{"nctId":"NCT01080300","briefTitle":"Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women","startDateStruct":{"date":"2010-08"},"conditions":["Hot Flashes"],"count":600,"armGroups":[{"label":"Gabapentin Extended Release","type":"EXPERIMENTAL","interventionNames":["Drug: Gabapentin Extended Release"]},{"label":"Placebo","type":"OTHER","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Gabapentin Extended Release","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Generally healthy, postmenopausal women who seek treatment for hot flashes\n* Patients using hormone replacement therapy(HRT) must be willing to discontinue treatment\n* Patients must be experiencing moderate to severe hot flashes\n* Patients must be able to sign the informed consent\n* Patients must be able to enter simple commands and complete questionnaires on the frequency and severity of their hot flashes using an electronic diary\n\nOther inclusions apply.\n\nExclusion Criteria:\n\n* Patients with hypersensitivity to Gabapentin\n* Patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss\n* Patients treated with estrogen pellets or injectable progestin drug therapy within 6 months.\n* Patients currently treated with Gabapentin or Pregabalin for any indication, including vasomotor symptoms\n\nOther exclusions apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.","description":"G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.72","spread":null},{"groupId":"OG001","value":"-5.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.64","spread":null},{"groupId":"OG001","value":"-6.50","spread":null}]}]}]},{"type":"PRIMARY","title":"G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.","description":"G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as \"Mild\" (1), \"Moderate\" (2), and \"Severe\" (3)) at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":null},{"groupId":"OG001","value":"-0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":null},{"groupId":"OG001","value":"-0.46","spread":null}]}]}]},{"type":"SECONDARY","title":"G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.","description":"G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 24 of the efficacy treatment period compared with Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.99","spread":null},{"groupId":"OG001","value":"-7.91","spread":null}]}]}]},{"type":"SECONDARY","title":"G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.","description":"G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as \"Mild\" (1), \"Moderate\" (2), and \"Severe\" (3)) at Week 24 of the efficacy treatment period compared with Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.86","spread":null},{"groupId":"OG001","value":"-0.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.","description":"Proportion of patients who were categorized as \"very much\" or \"much improved\" for PGIC at Week 12 and Week 24. Scale range is 6 categories: \"minimum value = very much worse\" to \"maximum value = very much improved\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.","description":"Proportion of patients who were categorized as \"very much\" or \"much improved\" in CGIC at Week 12 and Week 24. Scale range is 6 categories: \"minimum value = very much worse\" to \"maximum value = very much improved\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With 75% or Greater Reduction in Average Daily Frequency of Moderate to Severe Hot Flashes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With 75% or Greater Reduction in Average Daily Severity Score of Moderate to Severe Hot Flashes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Weeks 4, Week 12, and Week 24 in Average Daily Sleep Interference Score.","description":"Sleep Interference Score Range: Minimum value = 0, maximum value = 10 Lower scores indicate better outcome (ie, less interference)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.67","spread":null},{"groupId":"OG001","value":"-1.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.09","spread":null},{"groupId":"OG001","value":"-2.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.15","spread":null},{"groupId":"OG001","value":"-2.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in Sleep Quality Scores, Measured by the Insomnia Severity Index (ISI) to Week 4, Week 12, and Week 24 of the Efficacy Treatment Period.","description":"Insomnia Severity Index (ISI) scored on 4-point Likert-scales ('0' not at all - '4' extremely) for 7 sub-categories. Final score is sum of each sub-category generating a total sleep quality score (0-28). Minimum value = 0, maximum value = 28 (Lower scores indicate better outcome (ie, less severity)).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.47","spread":null},{"groupId":"OG001","value":"-4.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.02","spread":null},{"groupId":"OG001","value":"-5.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.71","spread":null},{"groupId":"OG001","value":"-4.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in Quality of Life Scores, Measured by the Menopause-Specific Quality of Life Questionnaire (MENQOL) to Weeks, 4, 12, 24 of the Efficacy Treatment Period.","description":"4 sub-categories each scored individually: Minimum value = 1, maximum value = 8.\n\nOverall summary score was mean of the 4 sub-category scores (minimum = 1 and maximum = 8).\n\nLower scores indicate better outcome (ie, less severity)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":null},{"groupId":"OG001","value":"-0.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":null},{"groupId":"OG001","value":"-0.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":null},{"groupId":"OG001","value":"-0.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety of G-ER Measuring Columbia-Suicide Severity Rating Scale (C-SSRS).","description":"Columbia-Suicide Severity Rating Scale (C-SSRS). Subjects were classified as 0=no suicidal ideation or 1=suicidal ideation. Outcome Measure is number of participants with or without suicidal ideation.\n\nHigher counts without suicidal ideation = better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"260","spread":null},{"groupId":"OG001","value":"257","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"224","spread":null},{"groupId":"OG001","value":"215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"271","spread":null},{"groupId":"OG001","value":"266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"256","spread":null},{"groupId":"OG001","value":"243","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":300},"commonTop":["Headache","Dizziness","Upper respiratory tract infection","Somnolence"]}}}